29-Jan-2025 3:00 PM CST - Business Wire AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Fou
14-Nov-2024 6:00 AM CST - Business Wire AN2 Therapeutics to Participate at Upcoming Investor Conferences AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. Details of the events are as follows: 7th Annual Evercore HealthCONx Conference, December 3-5, 2024 Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corpo
13-Nov-2024 3:00 PM CST - Business Wire AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial. Treatment options for patients with refractory MAC lung disease are extremely limited. Many of these
29-Jan-2025 3:00 PM CST - Business Wire AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Fou
14-Nov-2024 6:00 AM CST - Business Wire AN2 Therapeutics to Participate at Upcoming Investor Conferences AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. Details of the events are as follows: 7th Annual Evercore HealthCONx Conference, December 3-5, 2024 Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corpo
13-Nov-2024 3:00 PM CST - Business Wire AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial. Treatment options for patients with refractory MAC lung disease are extremely limited. Many of these